HLB제약
10,790KRWMarket close of 10/20 (Tue)
Down -1.55%-170KRWMarket close of 10/20 (Tue)
Preliminary value right after the close — replaced by official KRX data tomorrow morningClose of 10/21 (Wed)10,580KRWDown -1.95%
Preliminary · just after the close · replaced by official KRX data tomorrow morning
- Open
- 10,960
- High
- 10,970
- Low
- 10,400
- Day range
- Day range low 10,400 high 10,970, open 10,960, close 10,790, previous close 10,960
- Volume
- 34×10K shares
- 3.7B KRW 0.12× the 20-session average
Market close of 10/20 (Tue)
Usual range
Nothing unusual in the 1 checked items
Free · no sign-inSource from 2021-05-17
Points to check
- Daily movenot verifiedOnly 14 daily bars to compare, so not verified
- Trading valuenot verifiedNot enough 20-session trading value data, so not verified
- Earningsnot verifiedThe last four quarters are incomplete, so not verified
The other 3
- Recent filingsnot verified
- Foreign & institutionalnot verified
- Data date10/20 (Tue)Market close
See the full check report
Quarterly results · Q1 2026
- Revenue65.7B KRW
- vs. year ago
- —
- vs. prior quarter
- —
- Operating income1.0B KRW
- vs. year ago
- —
- vs. prior quarter
- —
- Operating margin1.6%
- vs. year ago
- —
- vs. prior quarter
- —
Quarterly operating income trend
As of the latest official close · 2026-10-20Valuation filing date · 2026-05-13Same sector · 바이오 R&D
Down -2.19%· 16 of 64 stocks up, preferred shares excluded · trading value 190.5B KRW
| Stock | 20D | Change | Trading value |
|---|---|---|---|
| 알테오젠 | Close over the last 20 sessions -9.6% | Down -3.35% | 51.1B KRW |
| 올릭스 | Close over the last 20 sessions -12.2% | Down -4.03% | 19.1B KRW |
| 디앤디파마텍 | Close over the last 20 sessions -11.8% | Down -1.93% | 15.1B KRW |
| 리가켐바이오 | Close over the last 20 sessions -15.4% | Down -1.41% | 12.1B KRW |
| 프로티나 | Close over the last 20 sessions +31.8% | Up +7.38% | 10.0B KRW |
Schedule
- Next data 10/22 (Thu) after 08:50
Investor flows, financials and valuation are provided for 369 stocks. These stocks account for about 81% of trading value, about 92% of market capitalisation. Coverage status →
For information only, not a solicitation to invest. Investment decisions and their results are your own responsibility.